Anavex Life Sciences (AVXL) Shares Outstanding (Diluted Average) (2010 - 2025)
Anavex Life Sciences recorded quarterly Shares Outstanding (Diluted Average) of $89.0 million in Q4 2025, up 4.39% quarter-over-quarter from $85.3 million in Q3 2025, and up 4.98% year-over-year from $84.8 million in Q4 2024.
Anavex Life Sciences' Shares Outstanding (Diluted Average) history runs 13 years deep, the most recent figure standing at $89.0 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Diluted Average) rose 4.98% year-over-year to $89.0 million; the TTM figure through Dec 2025 stood at $89.0 million (up 4.98% YoY), while the FY2025 annual figure was $85.3 million, up 2.18% from the prior year.
- Shares Outstanding (Diluted Average) came in at $89.0 million for Q4 2025 at Anavex Life Sciences, up from $85.3 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $89.0 million in Q4 2025 to a low of $69.8 million in Q3 2021.
- A 5-year average of $81.5 million and a median of $82.5 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
- Across the five-year window, Shares Outstanding (Diluted Average) climbed 10.18% in 2022 and grew 2.18% in 2025, its largest moves.
- Anavex Life Sciences' Shares Outstanding (Diluted Average) stood at $69.8 million in 2021, then increased by 11.71% to $78.0 million in 2022, then advanced by 5.26% to $82.1 million in 2023, then grew by 3.32% to $84.8 million in 2024, then grew by 4.98% to $89.0 million in 2025.
- According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods registered $89.0 million, $85.3 million, and $85.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | 89.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 89.03 Mn |
| Sep 30, 2025 | 85.29 Mn |
| Jun 30, 2025 | 85.09 Mn |
| Mar 31, 2025 | 84.94 Mn |
| Dec 31, 2024 | 84.81 Mn |
| Sep 30, 2024 | 83.47 Mn |
| Jun 30, 2024 | 83.02 Mn |
| Mar 31, 2024 | 82.46 Mn |
| Dec 31, 2023 | 82.08 Mn |
| Sep 30, 2023 | 79.79 Mn |
| Jun 30, 2023 | 79.05 Mn |
| Mar 31, 2023 | 78.14 Mn |
| Dec 31, 2022 | 77.98 Mn |
| Sep 30, 2022 | 76.91 Mn |
| Sep 30, 2021 | 69.80 Mn |
| Mar 31, 2017 | 41.16 Mn |
| Dec 31, 2016 | 38.39 Mn |
| Sep 30, 2016 | 35.15 Mn |
| Jun 30, 2016 | 34.96 Mn |
| Mar 31, 2016 | 35.21 Mn |
| Dec 31, 2015 | 33.97 Mn |
| Sep 30, 2015 | 18.58 Mn |
| Jun 30, 2015 | 15.44 Mn |
| Mar 31, 2015 | 13.61 Mn |
| Dec 31, 2014 | 12.91 Mn |
| Sep 30, 2014 | 9.80 Mn |
| Jun 30, 2014 | 39.26 Mn |
| Mar 31, 2014 | 37.88 Mn |
| Dec 31, 2013 | 43.93 Mn |
| Sep 30, 2013 | 31.91 Mn |
| Jun 30, 2013 | 30.24 Mn |
| Mar 31, 2013 | 30.24 Mn |
| Dec 31, 2012 | 30.24 Mn |
| Sep 30, 2012 | 28.17 Mn |
| Jun 30, 2012 | 28.36 Mn |
| Mar 31, 2012 | 27.34 Mn |
| Dec 31, 2011 | 26.74 Mn |
| Sep 30, 2011 | 25.17 Mn |
| Jun 30, 2011 | 24.91 Mn |
| Mar 31, 2011 | 24.71 Mn |
| Dec 31, 2010 | 24.27 Mn |
| Sep 30, 2010 | 21.44 Mn |